Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.
Michael A. Kolodziej, MD
Advertisement
Articles by Michael A. Kolodziej, MD
A lively discussion on Foundation Medicine's approach to creating genomic profiles.
Advertisement
Latest Updated Articles
- Grappling With the Fallout of Genetic Testing, in Oncology and Beyond
Published: January 29th 2014 | Updated:
- Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
Published: January 29th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
